PPARG and pulmonary arterial hypertension: This could involve the peroxisome proliferator-activated receptor-γ (PPARγ), which via a mechanism that appears independent of cAMP generation, could play a significant role in mediating the anti-proliferative effects of treprostinil in human PASMCs isolated from PAH patients [16].